Prevalence of G6PD Viangchan variant in malaria endemic areas in Lao PDR: an implication for malaria elimination by 2030.
Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Disease Eradication
/ methods
Female
Genotype
Glucosephosphate Dehydrogenase
/ analysis
Glucosephosphate Dehydrogenase Deficiency
/ epidemiology
Hemolysis
Humans
Infant
Infant, Newborn
Laos
/ epidemiology
Malaria, Vivax
/ drug therapy
Male
Middle Aged
Prevalence
Primaquine
/ adverse effects
Rural Population
Sequence Analysis, DNA
Young Adult
Glucose-6-phosphate dehydrogenase deficiency
Laos
Malaria elimination
Plasmodium vivax
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
12 Mar 2019
12 Mar 2019
Historique:
received:
10
01
2019
accepted:
08
03
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
17
4
2019
Statut:
epublish
Résumé
Primaquine is effective against the latent liver stage of Plasmodium vivax. Eliminating the latent liver stage of P. vivax is one of the necessary conditions to achieve the goal of malaria elimination in Lao People's Democratic Republic (PDR) by 2030. However, people with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of haemolysis when ingesting primaquine. The aim of this study was to detect the prevalence of the G6PD Viangchan variant, which is said to be common in Lao PDR and which can result in severe haemolysis in patients exposed to primaquine. Blood samples were collected from villagers in three malaria endemic provinces: Champasak and Savannakhet in the south, and Phongsaly in the north. Each blood sample was semi-quantitatively assayed for G6PD enzyme activity using the G6PD Assay Kit-WST Lyophilized (DOJINDO Laboratories, Japan). Blood samples that were found to be G6PD deficient were sequenced to detect G6PD Viangchan mutation. In total, 2043 blood samples were collected from Phongsaly (n = 426, 20.9%), Savannakhet (n = 924, 45.2%), and Champasak (n = 693, 33.9%) provinces in Lao PDR from 2016 to 2017. Of these, 964 (47.2%) were taken from male villagers and 1079 (52.8%) were taken from female villagers. G6PD Viangchan mutation was not detected in Phongsaly province in this study. In Savannakhet province, 48 of the 924 samples (45 males, 3 females) had the G6PD Viangchan mutation (n = 48, 5.2%). In Champasak province, 42 of the 693 samples (18 males, 24 females) had the G6PD Viangchan mutation (n = 42, 6.1%). G6PD Viangchan variant, which can cause severe haemolysis in the carrier when exposed to primaquine, was detected among 6.1% of the villagers in Champasak and 5.2% in Savannakhet but not in Phongsaly in this study. G6PD Viangchan variant might be common in the south of Laos but not so in the north. In the north, other G6PD deficiency variants might be more prevalent. However, in order not to overlook anyone and ensure a safe primaquine therapy for people living in malaria endemic areas in Lao PDR, G6PD testing is necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Primaquine is effective against the latent liver stage of Plasmodium vivax. Eliminating the latent liver stage of P. vivax is one of the necessary conditions to achieve the goal of malaria elimination in Lao People's Democratic Republic (PDR) by 2030. However, people with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of haemolysis when ingesting primaquine. The aim of this study was to detect the prevalence of the G6PD Viangchan variant, which is said to be common in Lao PDR and which can result in severe haemolysis in patients exposed to primaquine.
METHODS
METHODS
Blood samples were collected from villagers in three malaria endemic provinces: Champasak and Savannakhet in the south, and Phongsaly in the north. Each blood sample was semi-quantitatively assayed for G6PD enzyme activity using the G6PD Assay Kit-WST Lyophilized (DOJINDO Laboratories, Japan). Blood samples that were found to be G6PD deficient were sequenced to detect G6PD Viangchan mutation.
RESULTS
RESULTS
In total, 2043 blood samples were collected from Phongsaly (n = 426, 20.9%), Savannakhet (n = 924, 45.2%), and Champasak (n = 693, 33.9%) provinces in Lao PDR from 2016 to 2017. Of these, 964 (47.2%) were taken from male villagers and 1079 (52.8%) were taken from female villagers. G6PD Viangchan mutation was not detected in Phongsaly province in this study. In Savannakhet province, 48 of the 924 samples (45 males, 3 females) had the G6PD Viangchan mutation (n = 48, 5.2%). In Champasak province, 42 of the 693 samples (18 males, 24 females) had the G6PD Viangchan mutation (n = 42, 6.1%).
CONCLUSIONS
CONCLUSIONS
G6PD Viangchan variant, which can cause severe haemolysis in the carrier when exposed to primaquine, was detected among 6.1% of the villagers in Champasak and 5.2% in Savannakhet but not in Phongsaly in this study. G6PD Viangchan variant might be common in the south of Laos but not so in the north. In the north, other G6PD deficiency variants might be more prevalent. However, in order not to overlook anyone and ensure a safe primaquine therapy for people living in malaria endemic areas in Lao PDR, G6PD testing is necessary.
Identifiants
pubmed: 30866940
doi: 10.1186/s12936-019-2715-0
pii: 10.1186/s12936-019-2715-0
pmc: PMC6416863
doi:
Substances chimiques
G6PD protein, human
EC 1.1.1.49
Glucosephosphate Dehydrogenase
EC 1.1.1.49
Primaquine
MVR3634GX1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
75Références
Am Fam Physician. 2005 Oct 1;72(7):1277-82
pubmed: 16225031
Haematologica. 2006 Oct;91(10):1303-6
pubmed: 17018377
Acta Med Okayama. 2007 Aug;61(4):213-9
pubmed: 17726510
Am J Trop Med Hyg. 2007 Oct;77(4):779-89
pubmed: 17978087
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):79-87
pubmed: 18165478
Lancet. 2008 Jan 5;371(9606):64-74
pubmed: 18177777
J Vector Borne Dis. 2008 Jun;45(2):98-104
pubmed: 18592838
Blood Cells Mol Dis. 2012 Mar 15;48(3):154-65
pubmed: 22293322
PLoS Negl Trop Dis. 2012;6(9):e1814
pubmed: 22970336
PLoS Med. 2012;9(11):e1001339
pubmed: 23152723
Clin Microbiol Rev. 2013 Jan;26(1):36-57
pubmed: 23297258
Lancet. 2013 May 25;381(9880):1845-54
pubmed: 23706801
Malar J. 2013 Nov 04;12:391
pubmed: 24188096
Malar J. 2013 Nov 15;12:418
pubmed: 24228846
Pathog Glob Health. 2013 Dec;107(8):475-9
pubmed: 24428831
Malar J. 2014 Feb 25;13:70
pubmed: 24568147
Mem Inst Oswaldo Cruz. 2014 Aug;109(5):553-68
pubmed: 25141282
Malar J. 2014 Nov 03;13:418
pubmed: 25363455
Malar J. 2014 Dec 08;13:481
pubmed: 25486908
Malar J. 2015 Mar 05;14:103
pubmed: 25890368
Pathog Glob Health. 2015 May;109(3):93-106
pubmed: 25943156
PLoS Med. 2017 Feb 7;14(2):e1002224
pubmed: 28170391
BMJ Glob Health. 2017 Aug 19;2(3):e000415
pubmed: 29082022
PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006148
pubmed: 29261647
Malar J. 2018 Jun 1;17(1):218
pubmed: 29859089
Malar J. 2019 Jan 23;18(1):20
pubmed: 30674319